Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX), a leading global medical technology company, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025, at 2:00 pm Eastern Time. Investors and interested parties can access the live webcast through BD's investor relations website at investors.bd.com. A replay of the presentation will be made available on the same platform after the event concludes.

New groundbreaking studies published in The Lancet Oncology and Cancer Medicine reveal that cancer patients face significantly higher risks of developing antimicrobial resistant (AMR) infections compared to non-cancer patients. The research, conducted by the Cancer and AMR Consortium including BD (NYSE: BDX), analyzed over 1.6 million bacterial isolates from 198 outpatient facilities and 4.6 million hospital admissions in the U.S. Key findings show AMR rates were 1-3 times higher in cancer patients, with some specific pathogen combinations up to 5 times greater in outpatient settings. For hospitalized cancer patients, the risk was 1.5-2 times higher. The studies highlight critical concerns about AMR's impact on cancer treatment effectiveness, particularly for innovative therapies like CAR T-cell therapy, and emphasize the need for enhanced infection prevention programs and diagnostic tools.

BD (NYSE: BDX) has launched the BD FACSDiscover™ A8 Cell Analyzer, the world's first cell analyzer combining spectral and real-time cell imaging technologies. The device features BD SpectralFX™ Technology, enabling analysis of up to 50+ characteristics of a single cell simultaneously, and BD CellView™ Image Technology for high-speed fluorescent imaging. Key advancements include high-throughput automation, intuitive software workflows, and seamless integration with BD FACSDiscover™ Cell Sorters and Reagents. The analyzer comes with updated BD FACSChorus™ Software and FlowJo™ v11 analysis software, making it particularly valuable for translational research and immuno-oncology applications. This breakthrough technology allows researchers to uncover deeper cellular insights with increased ease and throughput, while managing budget constraints.

BD (NYSE: BDX) has announced it will host an audio webcast on August 7, 2025, at 8 a.m. ET to discuss its third quarter fiscal 2025 financial results. The quarter ends on June 30, 2025. During the webcast, management will present the quarterly financial performance and provide updates on the company's operations and strategy.

The webcast will be accessible through BD's investor relations website, with presentation materials and a summary of financial information to be released prior to the call. A replay of the webcast will be available on the same website shortly after the event.

BD (BDX) reported Q2 fiscal 2025 results with revenues of $5.3 billion, up 4.5% as reported and 0.9% organic growth. Adjusted diluted EPS reached $3.35, a 5.7% increase from the previous year. The company updated its fiscal 2025 guidance, now expecting revenues between $21.8-21.9 billion with organic revenue growth of 3.0-3.5%. Adjusted EPS guidance was revised to $14.06-14.34, including an estimated $0.25 tariff impact. BD Medical segment showed strong performance with 12.7% growth, while Life Sciences and Interventional segments declined by 4.3% and 2.2% respectively. The company announced plans to invest $2.5 billion in U.S. manufacturing capacity over the next 5 years, reinforcing its position as the largest U.S. medical device manufacturer.

BD (Becton, Dickinson and Company), a global leader in medical technology, has announced its upcoming participation in the Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 1:00 pm Eastern Time.

Investors and interested parties can access the live webcast through the BD investor relations website at investors.bd.com. For those unable to attend the live presentation, a replay will be made available on the same platform after the event concludes.

BD (Becton, Dickinson and Company), a leading global medical technology company, has announced its latest quarterly dividend declaration. The company's Board of Directors has approved a quarterly dividend of $1.04 per common share.

Key details of the dividend announcement:

• Payment Date: June 30, 2025
• Record Date: June 9, 2025
• Annual Dividend Rate: $4.16 per share

This dividend announcement from the NYSE-listed company (BDX) demonstrates BD's commitment to providing regular returns to its shareholders.

BD (NYSE: BDX) has received FDA 510(k) clearance and launched the Phasix™ ST Umbilical Hernia Patch, marking a significant innovation in hernia repair as the first fully absorbable hernia patch specifically designed for umbilical hernias. The patch is made from Poly-4-hydroxybutyrate (P4HB), a biologically-derived material, combined with a Sepra® Technology hydrogel barrier.

The product maintains the same surgical technique as traditional permanent mesh patches, featuring a pocket and strap design for easy placement. It builds on the success of the Ventralex™ ST Hernia Patch family, which has over two million implants globally. Survey data shows 60% of patients prefer non-permanent mesh options, with 70% of surgeons willing to accommodate these preferences.

The Phasix™ family of products has demonstrated success with over 385,000 implants globally, supported by more than 85 clinical publications studying over 4,000 patients. The new patch is available in three sizes to accommodate various umbilical soft tissue defects.

BD (NYSE: BDX) has launched HemoSphere Alta™, an advanced hemodynamic monitoring platform featuring AI-driven algorithms to help clinicians manage blood pressure and flow during critical procedures. The platform introduces the first-of-its-kind Cerebral Autoregulation Index (CAI), which monitors brain blood flow stability using ForeSight IQ™ and Acumen IQ™ sensors.

The system includes the Acumen Hypotension Prediction Index (HPI)™ software, proven to reduce hypotension severity in multicenter studies. Notable features include a 15" high-resolution touchscreen, split-screen views, voice and gesture commands, and minimal pop-ups for improved user experience.

This launch represents the first major product from BD's Advanced Patient Monitoring business since its acquisition, advancing BD's position in smart, connected care technologies.